Burke; Jason P.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Burke; Jason P..The latest application filed is for "salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamid- o) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide".

Company Profile

7.11.14

Burke; Jason P. - Houston TX

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
GLS1 inhibitors for treating disease Grant 11,370,786 - Di Francesco , et al. June 28, 2	2022-06-28
Salt Forms And Polymorphs Of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamid- O) Pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide App 20210206745 - JONES; Philip ; et al.	2021-07-08
Gls1 Inhibitors For Treating Disease App 20210122744 - LEWIS; Richard Thomas ; et al.	2021-04-29
Substituted indole Mcl-1 inhibitors Grant 10,954,193 - Lee , et al. March 23, 2	2021-03-23
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamid- o)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide Grant 10,899,740 - Jones , et al. January 26, 2	2021-01-26
Gls1 Inhibitors For Treating Disease App 20200407353 - DI FRANCESCO; Maria Emilia ; et al.	2020-12-31
GLS1 inhibitors for treating disease Grant 10,766,892 - Di Francesco , et al. Sep	2020-09-08
GLS1 inhibitors for treating disease Grant 10,738,043 - Lewis , et al. A	2020-08-11
Gls1 Inhibitors For Treating Disease App 20190270736 - DI FRANCESCO; Maria Emilia ; et al.	2019-09-05
GLS1 inhibitors for treating disease Grant 10,344,025 - Di Francesco , et al. July 9, 2	2019-07-09
Salt Forms And Polymorphs Of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamid- O) Pyridazin-3-yl)-2-flu App 20190144425 - JONES; Philip ; et al.	2019-05-16
Gls1 Inhibitors For Treating Disease App 20190031651 - LEWIS; Richard Thomas ; et al.	2019-01-31
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido- ) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide Grant 10,150,753 - Jones , et al. Dec	2018-12-11
GLS1 inhibitors for treating disease Grant 10,125,128 - Lewis , et al. November 13, 2	2018-11-13
Substituted Indole Mcl-1 Inhibitors App 20180258039 - Lee; Taekyu ; et al.	2018-09-13
Substituted indole Mcl-1 inhibitors Grant 10,005,728 - Lee , et al. June 26, 2	2018-06-26
Tricyclic indole Mcl-1 inhibitors and uses thereof Grant 9,949,965 - Lee , et al. April 24, 2	2018-04-24
GLS1 inhibitors for treating disease Grant 9,809,588 - Di Francesco , et al. November 7, 2	2017-11-07
Gls1 Inhibitors For Treating Disease App 20170291895 - DI FRANCESCO; Maria Emilia ; et al.	2017-10-12
Gls1 Inhibitors For Treating Disease App 20170001996 - Lewis; Richard Thomas ; et al.	2017-01-05
Substituted Indole Mcl-1 Inhibitors App 20160214934 - Lee; Taekyu ; et al.	2016-07-28
Tricyclic Indole Mcl-1 Inhibitors And Uses Thereof App 20160106731 - Lee; Taekyu ; et al.	2016-04-21
Gls1 Inhibitors For Treating Disease App 20160009704 - Di Francesco; Maria Emilia ; et al.	2016-01-14
Gls1 Inhibitors For Treating Disease App 20160002248 - Di Francesco; Maria Emilia ; et al.	2016-01-07
Gls1 Inhibitors For Treating Disease App 20160002204 - Di Francesco; Maria Emilia ; et al.	2016-01-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.